PATENT CLAIM ANALYSIS

Application Number: 15986577
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-12
Patent Classification: ["514", "364000"]

Abstract:
Use of glu-tubulin as a biomarker for predicting the response to a compound, preferably resistance of a disease such as cancer in a subject to said compound, wherein the compound is a furazanobenzimidazole compound of general formula (I).

Claim (Index 43):
The method of  claim 38 , wherein the protein sequence of glu-tubulin proteins is selected from the groups consisting of SEQ ID No. 1, SEQ ID 2, SEQ ID 3, SEQ ID 4, homologues, mutant forms, allelic variants, isoforms, splice variants and proteins with sequences having at least 75% identity to SEQ ID 1 to SEQ ID 4, with the proviso that glutamate is the final amino acid at the C terminal of the protein.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 93.0
- Lexical Diversity: 1.43333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13980208', '13983887', '15294157', '13979955', '14005680']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8766710069081799
- 35 USC 102 Novelty (BERT): 0.6911559850109543
- Combined Prediction Score: 0.8581195047184573
- Mean Citation Score: 686.2745000000001
- Max Citation Score: 729.4968
- Similarity Product: 692.8998990205763

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test